

## Repeatability and reproducibility of in-vivo brain temperature measurements

1 Ayushe A. Sharma<sup>1,4,5</sup>, Rodolphe Nenert<sup>2,5</sup>, Christina Mueller<sup>1</sup>, Andrew Maudsley<sup>6</sup>, Jarred  
2 Younger<sup>1</sup>, and Jerzy P. Szaflarski<sup>2,3,4,5</sup>

3

4 Departments of <sup>1</sup>Psychology, <sup>2</sup>Neurology, <sup>3</sup>Neurosurgery, and <sup>4</sup>Neurobiology, University of Alabama  
5 at Birmingham (UAB), Birmingham, AL, USA

6 <sup>5</sup>University of Alabama at Birmingham Epilepsy Center (UABEC), Birmingham, AL, USA

7 <sup>6</sup>Department of Radiology, University of Miami School of Medicine, Miami, FL, USA

### 8 \* Correspondence:

9 Ayushe Sharma, UAB Epilepsy Center, University of Alabama at Birmingham, Department of  
10 Neurology, 1719 6<sup>th</sup> Avenue South, CIRC 312, Birmingham, AL 35249-0021, USA. Email address:  
11 [sharma87@uab.edu](mailto:sharma87@uab.edu).

12 **Keywords: MRS, brain temperature, MR thermometry, neuroinflammation, neuroimaging**

13

14

15

16

17

18

19

20

21

22

23

24

25

## Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS

### 26 ABSTRACT

27 **Background.** Magnetic resonance spectroscopic imaging (MRSI) is a neuroimaging technique that  
28 can be used to noninvasively map brain temperature (i.e., thermometry) over a large brain volume.  
29 To date, intra-subject reproducibility of MRSI-based brain temperature (MRSI-t) has not been  
30 investigated. The objective of this repeated measures MRSI-t study was to establish intra-subject  
31 reproducibility and repeatability of brain temperature, as well as typical brain temperature range.

32 **Methods.** Healthy participants aged 23-46 years (N=18; 7 females) were scanned at two time points,  
33 ~12-weeks apart. Volumetric MRSI data were processed by reconstructing metabolite and water  
34 images using parametric spectral analysis. Brain temperature was derived using the frequency  
35 difference between water and creatine ( $T_{CRE}$ ) for 47 regions of interest (ROIs) delineated by the  
36 modified Automated Anatomical Labeling (AAL) atlas. Reproducibility was measured using the  
37 coefficient of variation for repeated measures (COVrep), and repeatability was determined using the  
38 standard error of measurement (SEM). For each region, the upper and lower bounds of Minimal  
39 Detectable Change (MDC) were established to characterize the typical range of  $T_{CRE}$  values.

40 **Results.** The mean global brain temperature over all subjects was 37.2°C, with spatial variations  
41 across ROIs. There was a significant main effect for time ( $F(1, 1591)=37.0, p < 0.0001$ ) and for brain  
42 region ( $F(46, 1591)=2.66, p<0.0001$ ). The time\*brain region interaction was not significant ( $F(46,$   
43  $1591)=0.80, p=0.83$ ). Participants'  $T_{CRE}$  was stable for each ROI across both time points, with ROIs'  
44 COVrep ranging from 0.81 – 3.08% (mean COVrep = 1.92%); 30 ROIs had a COVrep < 2.0%.

45 **Conclusions.** Brain temperature demonstrated subtle regional variations that were highly consistent  
46 between both time points, indicating high reproducibility and repeatability of MRSI-t. MRSI-t may  
47 be a promising diagnostic, prognostic, and therapeutic tool for non-invasively monitoring  
48 pathological brain temperature changes when other modalities are unrevealing. However, further  
49 studies of healthy participants with larger sample size(s) and numerous repeated acquisitions are  
50 imperative for establishing a reference range of typical brain  $T_{CRE}$ , as well as the threshold above  
51 which  $T_{CRE}$  is likely pathological.

52

53

54

55

56

57

58

59

60

61

## 62 1 INTRODUCTION

63 Neuroinflammation is increasingly implicated in the initiation and maintenance of a number  
64 of neurodegenerative diseases, including multiple sclerosis, Alzheimer’s Disease, and epilepsy  
65 (Lucas et al., 2006; Amor et al., 2010; Maroso et al., 2010). Structural and functional magnetic  
66 resonance imaging (MRI) studies are informative but frequently provide an incomplete clinical  
67 characterization of focal tissue abnormalities. In the context of surgical intervention for epilepsy  
68 management, patients experience worse long-term outcomes when MRI proves unremarkable  
69 (Alberts et al.; Salmenpera et al., 2007; Giorgio and De Stefano, 2010; Finke, 2018; Sharma and  
70 Szaflarski, 2020). Therefore, there is a dire need to identify a sensitive and specific *in vivo*  
71 biomarker of neuroinflammatory pathophysiology. Currently available approaches are invasive  
72 and/or costly (e.g., lumbar puncture, positron emission tomography [PET]). Further, PET relies on  
73 the use of radioisotopes that *may* localize key neuroinflammatory cells, but variable quantitative  
74 accuracy, limited bioavailability, and unclear specificity of ligand-target binding are critical gaps that  
75 limit its clinical utility (Hamelin et al.; Best et al., 2019; Vivash and OBrien, 2016; Dickstein et al.,  
76 2019; Ghadery et al., 2019; Sharma and Szaflarski, 2020). Thus, the question remains: how can we  
77 non-invasively localize neuroinflammation in a living human brain?

78 Since the focal inflammatory response generates focal changes in temperature, brain  
79 temperature mapping may be a promising proxy for diagnosing and monitoring the progression of  
80 neurological diseases characterized by metabolic and homeostatic disruptions (Ene Mrozek et al.;  
81 Wang et al., 2014). Brain temperature correlates well with systemic temperature during healthy  
82 states, generally measuring 0.5–1°C higher than core body temperature (Rossi et al., 2001; Wang et  
83 al., 2014). During pathological processes such as neuroinflammation, increased metabolic demands  
84 overwhelm the brain’s already limited cooling mechanisms and drive brain temperature by 1-  
85 2°C higher than core body temperature (Rossi et al., 2001). As neuroinflammatory phenomena such  
86 as leukocyte extravasation and accumulation, blood brain barrier permeability, and even cerebral  
87 edema increase, so does brain temperature (Dietrich et al., 1996, 1998; Chatzipanteli et al., 2000;  
88 Sharma and Hoopes, 2003).

89 Of the ways we can measure brain temperature, magnetic resonance spectroscopic imaging  
90 (MRSI) is the most non-invasive and economical. Brain temperature can be derived from MRSI data  
91 by calculating the frequency difference between the temperature-sensitive water peak and one or  
92 more metabolite peaks that are temperature-insensitive (Maudsley et al., 2017). MRSI-based brain  
93 temperature (MRSI-t) measurement correlates well with the recordings of implanted probes, as  
94 indicated by phantom and experimental studies (Cady et al., 1995; Corbett et al., 1995). Brain  
95 temperature has already been approximated using MRSI in a number of contexts: healthy adults,  
96 ischemic stroke, neonatal encephalopathy, myalgic encephalitis/chronic fatigue syndrome, and  
97 rheumatoid arthritis (Maudsley et al., 2010; Mueller et al., 2019, 2020; Zhang et al., 2020). The  
98 majority of previous studies have performed MRSI-t measurements only at a single brain location or  
99 limited spatial region, but it has recently been demonstrated that the measurement can be obtained  
100 using a volumetric echo-planar spectroscopic imaging (EPSI) acquisition to create temperature maps  
101 over a large fraction of the brain volume (Maudsley et al., 2006, 2017). Limited data are available on  
102 the reproducibility and reliability of MRSI-t using volumetric EPSI. Previous work has established  
103 intra-subject reproducibility of serial EPSI acquisitions in a limited sample (N=2) at 5 one-week  
104 intervals, as well as that of successive EPSI acquisitions (2 per session) in a larger sample (N=32)  
105 (Maudsley et al., 2010; Veenith et al., 2014). However, the reproducibility and repeatability of  
106 MRSI-t using volumetric EPSI has only been established in a small sample (N=10), with 3  
107 acquisitions separated by one-week intervals (Zhang et al., 2020). Thus, the available data do not

## Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS

108 mirror a real-life clinical situation in which participants are typically exposed to a  
109 treatment/intervention for 12-16 weeks before a second measurement is collected.

110 To date, no study has investigated whether intra-subject reproducibility is maintained in a  
111 larger sample of healthy control participants with a longer duration between scans. Additionally, all  
112 previous studies have only reported the coefficient of variation (COV) and intraclass correlation  
113 coefficients as measures of reproducibility and repeatability; these data are useful, but the exact  
114 boundary at which a given region's brain temperature is normal versus above-normal (i.e., areas of  
115 focal neuroinflammation or other pathophysiological phenomena) remains uncertain (Maudsley et al.,  
116 2010; Zhang et al., 2020). Before MRSI-t can be used as a clinical tool for in vivo assessment of  
117 neuroinflammation, we must determine whether MRSI-based brain temperature estimates are reliable  
118 and reproducible over typical study periods. In addition to establishing bounds of normal global and  
119 region-level brain temperature, it is critical that we determine the bounds at which brain temperature  
120 is above-normal in each region. The objective of this study was to establish intra-subject  
121 reproducibility and repeatability of brain temperature derivations in healthy participants scanned  
122 twice, approximately 12 weeks apart. In addition to establishing typical mean brain temperature  
123 across regions, we aimed to define the bounds of typical vs. atypical (i.e., possibly abnormal) brain  
124 temperature by calculating region-level measures of Minimum Detectable Change (MDC). We  
125 hypothesized that mean brain temperature would range from 37.0 to 37.5°C. We also hypothesized  
126 that MDC would indicate brain temperatures to be atypical if  $\geq 0.5^\circ\text{C}$  above mean brain temperature.

127

## 128 **2 METHODS**

### 129 **2.1 Participants**

130 Healthy adult participants were recruited from the local area via word of mouth and IRB-  
131 approved study flyers. Interested participants contacted study personnel via phone or email.  
132 Participants were scheduled for their first study visit pending a phone screen for inclusion criteria and  
133 MR compatibility. The primary inclusionary criteria were: 1) age of 18 to 65 years, 2) ability to  
134 undergo MRI at 3-Tesla (e.g., no metal implants or claustrophobia), and 3) negative urine pregnancy  
135 test if female of childbearing potential. Written informed consent was obtained from all participants  
136 before collecting any clinical measures or imaging data.

### 137 **2.2 Study Visits**

138 Participants completed two study visits scheduled at the University of Alabama at  
139 Birmingham (UAB) Civitan International Neuroimaging Laboratory housed in the UAB Highlands  
140 Hospital. For most participants (N=14), visits were scheduled 10-12 weeks apart; for the last 4  
141 participants recruited, the second study visit was delayed by 5 - 7 weeks due to COVID-19 research  
142 restrictions. The mean overall time between visits was  $11.33 \pm 2.59$  weeks. During each study visit,  
143 participants completed 2 self-report questionnaires: the Hospital Anxiety and Depression Scale  
144 (HADS) and the Profile of Mood States (POMS) (Zigmond and Snaith, 1983; McNair et al., 1989).  
145 Prior to imaging, tympanic temperature measurements were collected using a Braun Pro 4000  
146 ThermoScan aural thermometer.

### 147 **2.3 Data Acquisition**

148 Participants were scanned on a 3T Siemens Magnetom Prisma scanner using a 20-channel  
149 head coil. T1-weighted structural images were acquired using a magnetization-prepared rapid  
150 gradient echo sequence with the following parameters: repetition time (TR)=2400 ms; echo time  
151 (TE)=2.22 ms; flip angle=8°; 208 slices (0.8 mm thick); matrix=256x256. Whole-brain metabolite  
152 MRSI data were collected using a 3-dimensional EPSI sequence (TR<sub>1</sub>=1500 ms, TR<sub>2</sub>=511 ms,  
153 TE=17.6 ms, lipid inversion-nulling with TI=198 ms; FOV=280x280x180mm; 5.6x5.6x14.4mm  
154 voxels). A separate water MRSI dataset was acquired using an interleaved acquisition with identical  
155 spatial encoding. We also acquired 2D arterial spin labeling (ASL) perfusion scans to rule out  
156 perfusion-related contributions to brain temperature and metabolite concentration measurements (Ene  
157 Mrozek et al.; Zhu et al., 2009; Rango et al., 2015). ASL data were acquired using a Proximal  
158 Inversion with Control of Off-Resonance Effects (PICORE) labeling scheme for background  
159 suppression. Sixty pairs of label/control ASL images were collected in the axial direction at a single  
160 inversion time of 1800ms, TR=2500ms, TE=16.18ms, 12 slices, 4x4x10 mm voxels.

## 161 **2.4 Data Processing**

162 Image reconstruction and spectral processing was completed within the Metabolite Imaging  
163 and Data Analysis System (MIDAS) software package (Maudsley et al., 2006). Raw metabolite and  
164 water MRSI data were reconstructed with interpolation to 64x64x32 and spatial smoothing, resulting  
165 in a voxel volume of approximately 1.5 cm<sup>2</sup>. Processing included B<sub>0</sub> inhomogeneity correction and  
166 formation of individual metabolite maps using a parametric spectral modelling method to quantify  
167 relative peak areas and resonance frequencies for resonances of N-acetylaspartate (NAA), creatine  
168 (CRE), choline, and water, as described by Maudsley et al. (Maudsley et al., 2006). For repeat  
169 studies, each MRSI dataset was spatially registered to the T1-weighted image of the first study.  
170 Maps of brain temperature were then calculated using the chemical shift difference between the CRE  
171 and water resonances ( $\Delta_{H20-CRE}$ ) according to the equation  $T_{CRE} = \square - 102.61(\Delta_{H20-CRE}) + 206.1^{\circ}C$   
172 (Maudsley et al., 2017). The CRE resonance was selected for the frequency reference as it is broadly  
173 distributed within the cells and as such is less sensitive to cellular-level changes of magnetic  
174 susceptibility with neuronal orientation (Maudsley et al., 2017). The resultant MRSI-t maps were  
175 then spatially registered to Montreal Neurological Institute (MNI) template at 2mm isotropic voxel  
176 resolution, which was also aligned with a modified version of the Automated Anatomical Labeling  
177 (AAL) atlas that delineated 47 regions of interest (ROIs) (Tzourio-Mazoyer et al., 2002; Maudsley et  
178 al., 2017).

179 Following initial processing, the atlas was mapped into subject space using an inverse spatial  
180 transformation algorithm within the MIDAS Project Review and Analysis (PRANA) module  
181 (Maudsley et al., 2006). The Map Integrated Spectrum (MINT) module within MIDAS was then  
182 used to compute mean estimates of metabolite concentrations, metabolite ratios, and brain  
183 temperature within each of the atlas-defined brain regions. Spectral integration was limited to voxels  
184 that had a fitted metabolite linewidth >12 Hz or <2Hz, and voxels were excluded if they had an  
185 outlying values of 2.5 times the standard deviation of all valid voxels in the image (Maudsley et al.,  
186 2006).

187 ASL data were processed using ASLtbx batch scripts with Statistical Parametric Mapping  
188 (SPM12; <http://www.fil.ion.ucl.ac.uk>) running in MatLab R2019b (The MathWorks, Inc., Natick,  
189 MA, USA) (Wang et al., 2008). Images were motion-corrected and smoothed with a 6 mm full-  
190 width-at-half-maximum (FWHM) Gaussian kernel to diminish motion artifacts and decrease noise  
191 for subsequent image subtraction. Cerebral blood flow (CBF) was quantified in ml/100g/min using  
192 simple subtraction between each tag/control pair (120 smoothed volumes, 60 pairs). Each



193 participant's mean CBF maps were then 1) registered to high-resolution structural space with affine  
194 registration, followed by 2) non-linear registration to MNI space.<sup>1</sup>

## 195 **2.5 Data Analysis**

196 Descriptive statistics and correlation analyses were conducted in IBM SPSS Version 26.0  
197 ([www.ibm.com/products/spss-statistics](http://www.ibm.com/products/spss-statistics)). Reproducibility of MRSI-t based  $T_{CRE}$  was evaluated using  
198 the coefficient of variation for repeated measures (COVrep) (Shechtman, 2013). Reliability was  
199 evaluated with the Standard Error of Measurement (SEM = square root of the  $MS_{ERROR}$  term from 2-  
200 way mixed ANOVA used to compute Cronbach's Alpha) (Weir, 2005). Minimal Detectable Change  
201 (MDC) was then calculated from SEM to provide a clinically meaningful basis for evaluating  $T_{CRE}$   
202 changes over repeated measures. Standard MDC was calculated at the 68<sup>th</sup> confidence interval (CI)  
203 (Weir, 2005). To investigate temporal and spatial variation in  $T_{CRE}$ , we performed a linear mixed  
204 effects analysis using GraphPad Prism version 8.0 for Mac (GraphPad Software, La Jolla, CA, USA,  
205 [www.graphpad.com](http://www.graphpad.com)).

206 In a secondary analysis, the relationship between  $T_{CRE}$  and metabolites and/or metabolite  
207 ratios implicated in neuroinflammatory disease was assessed. Metabolites of interest included myo-  
208 inositol, choline, NAA, and the combined signal of glutamine and glutamate (Glx) (Oz et al., 2014).  
209 Myo-inositol (MI) is a glial marker, with increased levels indicating glial activation or proliferation  
210 seen in neuroinflammation (Haris et al., 2011). Choline (total choline, tCho) is expressed in cell  
211 membranes, with increased levels indicating high cell turnover during inflammatory processes (Oz et  
212 al., 2014). NAA indicates neuronal health, with lower values representing axonal loss (Moffett et al.,  
213 2007; Oz et al., 2014). Due to evidence for creatine (total creatine, tCre) as a reference metabolite,  
214 metabolites were evaluated on the basis of their ratios with tCre (Maudsley et al., 2017). Spearman's  
215 rho ( $r_s$ ) correlation coefficients were calculated between  $T_{CRE}$ , each metabolite ratio of interest, and  
216 tympanic temperature using a two-tailed threshold of  $p < 0.05$ . Variables with  $r_s > |0.5|$  were evaluated  
217 as predictors of  $T_{CRE}$  in a multiple regression model. Independent samples t-tests assessed  
218 hemispheric (right vs left) differences in region-level  $T_{CRE}$ . Independent samples t-tests contrasting  
219 sex differences in global and region-level  $T_{CRE}$  were planned but not performed due to unequal sex  
220 distribution in the final dataset. Data quality was evaluated on the basis of 1) number of accepted  
221 voxels (%) following processing and 2) spectral linewidth.

222 Paired samples t-tests of participants' mean CBF maps contrasted cerebral perfusion between  
223 the two time points. This served as a measure of whether brain temperature differences – if present –  
224 could be attributed to perfusion differences.

225

## 226 **3 RESULTS**

### 227 **3.1 Participant Demographics and Metabolite Measures**

228 Twenty-one participants were recruited; 18 completed all study procedures and were included  
229 in the analyses (N=7 females). The mean age was  $30.39 \pm 7.47$  years (range 23–46 years).  
230 Descriptive statistics for study measures of temperature, blood flow, and inflammatory metabolite  
231 ratios were tabulated for both time points; global within-subject differences from time1 to time2 were  
232 computed with repeated measures t-tests (Table 1). The repeated measures t-tests revealed  
233 significant increase in HADS sub-scale Depression scores [ $t(17) = -4.12, p = 0.001$ ], though this change  
234 was not clinically significant and scores remained in the normal range (0-7) for both time points

235 (Zigmond and Snaith, 1983). Additionally, there was a global reduction in mean NAA/tCRE,  
236  $t(17)=2.19, p=0.04$ . Mean  $T_{CRE}$  was  $37.00^{\circ}\text{C}$  at time1 and  $37.40^{\circ}\text{C}$  at time2, with a global mean  $T_{CRE}$   
237 of  $37.2^{\circ}\text{C}$  across both time points. Box-and-whisker plots of  $T_{CRE}$  calculated at both time points are  
238 provided in Figure 1.

### 239 **3.2 Brain Temperature Reproducibility, Reliability, and Minimal Detectable Change**

240 The COVrep, our measure of reproducibility, ranged from 0.81 – 3.08% (mean 1.92%) across  
241 47 ROIs, with 30 ROIs having a COVrep < 2.0%. SEM ranged from 0.365 – 2.713 (mean  $1.295 \pm$   
242  $0.647$ ) (Table 2). The highest COVrep (3.08%) was in the R Fusiform Gyrus. Mean brain  
243 temperature was the lowest in the R and L putamen, R and L pallidum, R and L hippocampus, L and  
244 R anterior cingulum, R and L thalamus, and R insula (Table 2). Mean brain temperature was highest  
245 in the R occipital lobe, L and R precuneus, R and L frontal lobes, and R and L cuneus.

246 Based on the MDC, the  $T_{CRE}$  at which we consider brain temperature as atypical varies across  
247 brain regions (Table 2, Figure 2). When considering MDC computations at the 68<sup>th</sup> CI, the upper  
248 bounds of brain temperature indicating above-typical  $T_{CRE}$  ranged from  $37.57 - 41.49^{\circ}\text{C}$  (mean  $39.03$   
249  $\pm 1.14^{\circ}\text{C}$ ); the lower bounds indicating below-typical  $T_{CRE}$  ranged from  $33.74 - 36.91^{\circ}\text{C}$  (mean  
250  $35.37 \pm 0.80^{\circ}\text{C}$ ). According to MDC calculations, the  $T_{CRE}$  at which values are considered above-  
251 typical were highest in the following regions: R and L frontal lobes ( $41.49^{\circ}\text{C}$ ,  $40.99^{\circ}\text{C}$ ), R occipital  
252 lobe ( $41.38^{\circ}\text{C}$ ), L precentral gyrus ( $41.13^{\circ}\text{C}$ ), and L and R parietal lobes ( $40.92^{\circ}\text{C}$ ,  $41.03^{\circ}\text{C}$ ) (Table  
253 2, Figure 2). In addition to assessing these ROI-based measures, brain temperature maps visualized  
254 brain temperature changes within participants from time1 to time2 (Figure 3).

### 255 **3.3 Spatial and Temporal Variations in Brain Temperature**

256 A linear mixed effects model investigated the variation of  $T_{CRE}$  across 47 brain regions over 2  
257 time points. Fixed effects included time, brain region, and the interaction of time\*brain region, with  
258 participants considered random effects. In the case of a statistically significant interaction, we  
259 planned follow-up tests to assess pairwise differences using simple effects analysis. P-values were  
260 corrected for multiple comparisons by controlling the False Discovery Rate (FDR=0.05) with the  
261 two-stage step-up method of Benjamini, Krieger, and Yekutieli (Benjamini and Yekutieli, 2001). The  
262 interaction of time\*brain region was not significant ( $F(46, 1591)=0.80, p=0.83$ ). There was a significant  
263 main effect for time ( $F(1, 1591)=37.0, p<0.0001$ ), and for brain region ( $F(46, 1591)=2.66, p<0.0001$ ).

### 264 **3.4 Within-Subjects Variation in Cerebral Blood Flow**

265 Voxel-level repeated measures t-tests did not find significant within-subjects differences in  
266 mean CBF when comparing time1 vs time 2; the same results were found when mean  $T_{CRE}$  was included  
267 as a covariate. Further, participants' global CBF values did not change significantly from time1 to time2,  
268 as indicated by paired samples t-tests [ $t(17)=0.21, p=0.84$ ]. At time1, mean global CBF was  $70.77$   
269  $\pm 6.15$  mL/100g/min. At time2, mean global CBF was  $71.03 \pm 4.24$  mL/100g/min (Table 1). Mean  
270 CBF ranged from  $56.66 - 79.99$  mL/100g/min (Figure 3). Each participant's mean CBF maps for  
271 time1 and time2 are visualized alongside  $T_{CRE}$  maps (Figure 3). Mean CBF for all participants across  
272 both time points was  $70.90$  mL/100g/min.

### 273 **3.5 Relationship between Brain Temperature and Other Physiological Variables**

274 For major metabolites (tCre, tCho, NAA, and MI), COVrep (%) values are provided in Table  
275 4. In contrast to  $T_{CRE}$ , metabolite concentrations varied substantially across time. For tCho, mean

276 COVrep was 12.49% (range 3.13 – 84.52%); with the removal of outlying values for the R Precentral  
277 Gyrus, the COVrep range for tCho becomes limited to 3.13 – 34.44%. For tCre, mean COVrep was  
278 10.38% (range 4.35-22.08%). For NAA, mean COVrep was 6.93% (range 2.68 – 28.44%). Lastly,  
279 mean COVrep for MI was 16.05% (range 6.41-41.97%). The mean distribution of tCre, tCho, and  
280 NAA across regions at time1 is included in Figure 4.

281 Spearman correlations were run to test the relationship between  $T_{CRE}$  and the ratios MI/tCRE,  
282 NAA/tCRE, and Glx/tCRE (Table 5). There was a strong, positive correlation between  $T_{CRE}$  and  
283 NAA/tCRE ( $r_s=0.678, p<0.0001$ ), and a strong negative correlation between  $T_{CRE}$  and tCho/tCRE  
284 ( $r_s=-0.575, p<0.0001$ ). There was a moderate, positive statistically significant correlation between  
285  $T_{CRE}$  and Glx/tCRE,  $r_s=0.458, p=0.001$ . Lastly, there was a weak, negative correlation of statistical  
286 significance between  $T_{CRE}$  and MI/tCRE,  $r_s=-0.322, p=0.027$ . Based on results of correlation  
287 analysis, a multiple regression was performed to predict  $T_{CRE}$  from tCHO/tCRE, NAA/tCRE,  
288 Glx/tCRE and MI/tCRE. However, none of the metabolite ratios were significant predictors of  $T_{CRE}$ .

289 There were no significant differences in brain temperature when comparing left and right ROIs at  
290  $p<0.05$ , corrected for FDR. Due to unequal sex distribution of our participants in the final dataset, we  
291 did not perform independent samples t-tests to evaluate sex differences in global and regional  $T_{CRE}$ .

### 292 **3.6 Assessing Quality and Spectral Resolution**

293 Our data were of moderate to high quality as indicated by the spectral resolution and total  
294 percentage of voxels included in our final analysis. An average of 75.18 % of voxels within the brain  
295 met quality criteria across both timepoints ( $76.47 \pm 10.68\%$  of voxels at  $T_1$ ,  $73.89 \pm 12.39\%$  of  
296 voxels at  $T_2$ ), with a range of 48.13% to 89.53%. As indicated by the mean linewidth of 7.31 Hz  
297 (range, 6.39 - 8.69), our data also had high spectral resolution.

298 We performed *post-hoc* correlation analysis of SEM, COVrep, mean  $T_{CRE}$ , and ROI size to  
299 determine if there was an association between reproducibility, repeatability,  $T_{CRE}$ , and region size. ROI  
300 size was calculated by multiplying the mean # of voxels in each region (pre-processing) by the mean %  
301 accepted voxels after processing. To adjust for varying scale, SEM, COVrep, mean  $T_{CRE}$ , and ROI size  
302 were z-transformed. Reproducibility and repeatability (COVrep\*SEM) had a strong positive correlation  
303 ( $r=0.805, p<0.001$ ) (Table 6). Mean  $T_{CRE}$  had a moderate positive correlation with both SEM ( $r=0.487$ ,  
304  $p<0.001$ ) and ROI size ( $r=0.626, p<0.001$ ) (Table 6). Finally, in addition to its association with mean  
305  $T_{CRE}$ , ROI size had a moderate positive correlation with SEM ( $r=0.524, p<0.001$ ) (Table 6).

306

## 307 **4 DISCUSSION**

### 308 **4.1 Main Findings**

309 In this study, a global brain temperature of 37.2°C was found, with spatial variations across  
310 ROIs consistent with previous studies (Cady et al., 1995, 2011; Zhang et al., 2020). Also consistent  
311 with previous studies was a significant main effect for time ( $F(1, 1591)=37.0, p<0.0001$ ), and for brain  
312 region ( $F(46, 1591)=2.66, p<0.0001$ ). The central aim of this study was to evaluate whether intra-  
313 subject reproducibility is maintained in a large sample of healthy participants with longer duration  
314 between scans than previously investigated. Though this study acquired MRSI-t data with a much  
315 greater time interval between acquisitions (~12 weeks apart), the COVrep ranged from 0.81 – 3.08%  
316 (mean COVrep = 1.92%), with 30 ROIs having a COVrep < 2.0%. Thus,  $T_{CRE}$  was stable across all 47



## Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS

317 ROIs and paralleled results of previous studies of serial acquisitions or those separated by 1-week  
318 intervals (Maudsley et al., 2010; Thrippleton et al., 2014; Zhang et al., 2020). Another important  
319 question was whether timepoint has an impact on the mean brain temperature within a given ROI.  
320 Mixed effects analysis confirmed that brain temperature does change within ROIs as a function of  
321 time, as indicated by the lack of a significant interaction (time\*brain region,  $F(46, 1591)=0.80$ ,  
322  $p=0.83$ ). Interestingly, the highest  $T_{CRE}$  was found in 1) posterior regions affected by anterior-posterior  
323 gradient effects (L and R occipital lobe, L and R cuneus, L and R precuneus), and 2) large peripheral  
324 cortical regions (L and R frontal lobes, R parietal, L and R occipital). Large posterior regions  
325 demonstrated higher  $T_{CRE}$  with more within-subject variability and greater SEM. Based on MDC,  
326 atypical  $T_{CRE}$  ranged from 37.57 – 41.49°C. MDC was calculated at the 68<sup>th</sup> confidence interval (CI),  
327 but future work with larger sample sizes and more repeated acquisitions may enable MDC  
328 calculation at the 90<sup>th</sup> or 95<sup>th</sup> CIs. Based on the aforementioned findings, our study confirms  
329 previous findings of spatial brain temperature variations from structure to structure; even if time has a  
330 significant effect, this effect is distributed over regions, and does not change in magnitude as a  
331 function of ROI. Though  $T_{CRE}$  correlated moderately with some of the neuroinflammatory  
332 metabolites, the regression model indicated that none were significant predictors. Thus, the  
333 relationship between  $T_{CRE}$  and neuroinflammatory metabolites could not be fully assessed in this  
334 population, as would be expected for healthy participants without neuroinflammatory  
335 pathophysiology.

336 Maudsley et al. previously established tCRE as the reference metabolite for brain temperature  
337 derivations; this is because of its even distribution across cellular compartments (at least in the  
338 absence of disease), which renders tCRE the least susceptible to grey matter (GM) and white matter  
339 (WM) tissue-dependent frequency shifts (Maudsley et al., 2017). Given the difficulty of separating  
340 GM and WM within each ROI, we used tCRE as our reference metabolite. However, it is not always  
341 the case that tCRE is well-distributed or best reference metabolite – especially when considering  
342 neurodegenerative conditions characterized by significant changes in bioenergetics/metabolism. The  
343 posterior regions that indicated higher brain temperature and greater variability could be the result of  
344 anterior-posterior gradient due to acquisition, but may also be the result of visual stimulation effects  
345 from watching movies during scanning (Kauppinen et al., 2008; Rango et al., 2015). Future studies  
346 would benefit from acquiring data both with and without in-scanner visual stimulation.

## 347 4.2 Limitations and Other Considerations

348 Our study was limited by the heterogeneity of the participant population, limited age range  
349 (no participants >46 years), and acquisition-related methods that are inherently variable between- and  
350 within-participants. Additionally, we did not monitor or control for a number of variables that could  
351 alter brain temperature, including circadian rhythms, diurnal changes, hormonal variations (e.g., due  
352 to menstruation), or even environmental conditions (e.g., temperature in the scanner room). Our  
353 methodological limitations stem from two issues that critically impact all MRSI-t data: 1) magnetic  
354 field inhomogeneities and 2) interfering signal from water-containing structures (e.g., the aqueous  
355 humor of the eyes). Shimming during EPSI acquisition can substantially reduce magnetic field  
356 inhomogeneities and improve signal-to-noise ratio by adjusting spectral linewidth, but the process is  
357 time-consuming and difficult without substantial training. Though shimming greatly improves  
358 spectral linewidth, it cannot correct the spatial inhomogeneities present across structures and even  
359 within large brain regions – additionally, it is unclear whether these spatial inhomogeneities are truly  
360 artifact or a reflection of actual physiological processes. Signals from water-containing structures are  
361 typically masked with the placement of a saturation band placement during data acquisition. While  
362 this is effective to an extent, the saturation band is a 3D rectangular slab of fixed bounds and shape –

## Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS

363 it can only be angled to cover the eyes and sphenoidal sinuses, and there is currently no capacity for  
364 altering the curvature of the band. Depending on each participant's structural anatomy, the saturation  
365 band may cut off regions from regions of cortex in the frontal areas. Additionally, the placement and  
366 angling of this slab cannot be replicated from subject-to-subject or even within a subject across time  
367 points. As with our own data, these issues can result in missing or even heavily contaminated  
368 metabolite and temperature data for impacted ROIs, as voxels may not contain sufficient information  
369 or signals of sufficient quality.

370 A countless number of phenomena could theoretically impact brain temperature and weaken  
371 the ability to maintain sufficient reproducibility and reliability. Functional activity, time of day, and  
372 even transient hormonal fluctuations such as menstruation may impact MRSI-t-based estimates (Ene  
373 Mrozek et al.). Thrippleton et al limited data acquisition to afternoon hours to minimize diurnal  
374 temperature variation, and went so far as to recruit only male subjects to avoid the hormonal  
375 fluctuations that may impact brain temperature in females (Thrippleton et al., 2014). They  
376 additionally instructed their participants to refrain from eating, drinking, exercising, or going  
377 outdoors within 1 hour of scanning; even the temperature of the scanner room was regulated to obtain  
378 the most precise measurements (Thrippleton et al., 2014). These methods may be the reason for low  
379 error in repeated measurements ( $0.14^{\circ}\text{C}$ ), with less deviation between successive measurements. Of  
380 course, not all studies have the capacity to limit such phenomena, and one could argue that varied  
381 reference data in both sexes and across a varied number of experimental situations is imperative for  
382 fully understanding MRSI-t-based temperature estimates. Additionally, the calibrated equation we  
383 used for deriving  $T_{\text{CRE}}$  was developed on a more dated scanner model than that used for our study.  
384 There is disagreement over whether a calibrated formula derived phantom data is a worthwhile  
385 endeavor (Verius et al., 2019; Annink et al., 2020). The difference is minimal for short TE MRSI-t,  
386 but significant for long TE MRSI-t, resulting in a mean difference between derivations of up to  
387  $0.15^{\circ}\text{C}$  (Annink et al., 2020). Given this small but possibly significant difference, future studies  
388 would benefit from developing a calibrated temperature formula that accounts for conditions at their  
389 particular scanner. It is worth noting that a calibration would only impact the intercept of the  
390 temperature calculation, with no impact on the slope. Thus, calibration would have little impact on  
391 outcomes if all participants' data are acquired with the same sequence and identical temperature  
392 equation.

### 393 4.3 Conclusions

394 MRSI-t is a reliable and reproducible approach to measuring brain temperature, though future  
395 studies of larger sample size with more repeated acquisitions over long duration are necessary. We  
396 must also determine whether MRSI-t measurements of brain temperature are sensitive to the  
397 phenomenon we are attempting to visualize. Since this study included healthy participants only, the  
398 relationship between brain temperature and neuroinflammatory metabolites could not be fully  
399 assessed. Thus, the reference data this study provides must be applied to assessing patients with  
400 focal neuroinflammation. Before MRSI-t-based temperature can be utilized clinically, it is  
401 imperative to determine 1) if this tool can isolate focal brain temperature increases in regions of  
402 neuroinflammation and 2) if it can differentiate those with neuroinflammatory pathophysiology from  
403 those who are healthy.

404

## 405 5 DATA AVAILABILITY STATEMENT

## Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS

406 De-identified data will be made available upon reasonable request with IRB and data sharing  
407 approvals in place.

408

### 409 **6 ETHICS STATEMENT**

410 All study procedures were approved by the UAB Institutional Review Board. Written informed  
411 consent was obtained from all participants before initiating the protocol.

412

### 413 **7 CONFLICT OF INTEREST**

414 The authors declare that the research was conducted in the absence of any commercial or financial  
415 relationships that could be construed as a potential conflict of interest.

416

### 417 **8 AUTHOR CONTRIBUTIONS**

418 All authors listed have made substantial, direct, and intellectual contributions to the work. AAS, RN,  
419 and JPS: methodology and writing – review and editing. AAS and RN: data acquisition and  
420 processing. AAS and AM: methodology, data curation, and data visualization. CM, AM, JY: review  
421 and editing. AAS: formal analysis, writing—original draft. JPS: project supervision, funding  
422 acquisition, conceptualization, review, and writing—review and editing.

423

### 424 **9 FUNDING**

425 State of Alabama General Fund (“Carly’s Law”) and the UAB Epilepsy Center supported this study.  
426 Ms. Sharma is currently supported by an institutional training grant (T32-NS061788-13) from the  
427 National Institute of Neurological Disorders and Stroke (NINDS).

428

### 429 **10 ACKNOWLEDGEMENTS**

430 The authors thank Dr. Adam Goodman for helpful discussions regarding data analyses and  
431 visualization. This study was presented in part at the Annual Meeting of the Organization for Human  
432 Brain Mapping, Montreal, CA, 2020 (virtual presentation).

433

### 434 **11 REFERENCES**

435 Alberts, M. J., Faulstich, M. E., and Gray, L. Stroke With Negative Brain Magnetic Resonance  
436 Imaging. Available at: <http://ahajournals.org> [Accessed July 19, 2020].

437 Amor, S., Puentes, F., Baker, D., and Van Der Valk, P. (2010). Inflammation in neurodegenerative

**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**

- 438 diseases. *Immunology* 129, 154–169. doi:10.1111/j.1365-2567.2009.03225.x.
- 439 Annink, K. V., Groenendaal, F., Cohen, D., van der Aa, N. E., Alderliesten, T., Dudink, J., et al.  
440 (2020). Brain temperature of infants with neonatal encephalopathy following perinatal asphyxia  
441 calculated using magnetic resonance spectroscopy. *Pediatr. Res.*, 1–6. doi:10.1038/s41390-019-  
442 0739-3.
- 443 Benjamini, Y., and Yekutieli, D. (2001). THE CONTROL OF THE FALSE DISCOVERY RATE IN  
444 MULTIPLE TESTING UNDER DEPENDENCY.
- 445 Best, L., Ghadery, C., Pavese, N., Tai, Y. F., and Strafella, A. P. (2019). New and Old TSPO PET  
446 Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease.  
447 doi:10.1007/s11910-019-0934-y.
- 448 Cady, E. B., D’Souza, P. C., Penrice, J., and Lorek, A. (1995). The Estimation of Local Brain  
449 Temperature by in Vivo <sup>1</sup>H Magnetic Resonance Spectroscopy. *Magn. Reson. Med.* 33, 862–  
450 867. doi:10.1002/mrm.1910330620.
- 451 Cady, E. B., Penrice, J., and Robertson, N. J. (2011). Improved reproducibility of MRS regional brain  
452 thermometry by “amplitude-weighted combination.” *NMR Biomed.* 24, 865–872.  
453 doi:10.1002/nbm.1634.
- 454 Chatzipanteli, K., Alonso, O. F., Kraydieh, S., and Dietrich, W. D. (2000). Importance of  
455 posttraumatic hypothermia and hyperthermia on the inflammatory response after fluid  
456 percussion brain injury: Biochemical and immunocytochemical studies. *J. Cereb. Blood Flow*  
457 *Metab.* 20, 531–542. doi:10.1097/00004647-200003000-00012.
- 458 Corbett, R. J. T., Laptook, A. R., Tollefsbol, G., and Kim, B. (1995). Validation of a Noninvasive  
459 Method to Measure Brain Temperature In Vivo Using <sup>1</sup>H NMR Spectroscopy. *J. Neurochem.*  
460 64, 1224–1230. doi:10.1046/j.1471-4159.1995.64031224.x.
- 461 Dickstein, L. P., Liow, J., Austermuehle, A., Zoghbi, S., Inati, S. K., Zaghoul, K., et al. (2019).  
462 Neuroinflammation in neocortical epilepsy measured by PET imaging of translocator protein.  
463 *Epilepsia* 60, epi.15967. doi:10.1111/epi.15967.
- 464 Dietrich, W. D., Alonso, O., Busto, R., Prado, R., Zhao, W., Dewanjee, M. K., et al. (1998).  
465 Posttraumatic cerebral ischemia after fluid percussion brain injury: An autoradiographic and  
466 histopathological study in rats. *Neurosurgery* 43, 585–593. doi:10.1097/00006123-199809000-  
467 00105.
- 468 Dietrich, W. D., Alonso, O., Halley, M., and Busto, R. (1996). Delayed posttraumatic brain  
469 hyperthermia worsens outcome after fluid percussion brain injury: A light and electron  
470 microscopic study in rats. *Neurosurgery* 38, 533–541. doi:10.1097/00006123-199603000-  
471 00023.
- 472 Ene Mrozek, S., Vardon, F., and Geeraerts, T. Brain Temperature: Physiology and Pathophysiology  
473 after Brain Injury. *Anesthesiol. Res. Pract.* 2012, 13. doi:10.1155/2012/989487.
- 474 Finke, C. (2018). Diagnosing MRI-negative autoimmune diseases. *Neurol. - Neuroimmunol.*  
475 *Neuroinflammation* 5, e457. doi:10.1212/nxi.0000000000000457.

**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**

- 476 Ghadery, C., Best, L. A., Pavese, N., Tai, Y. F., and Strafella, A. P. (2019). PET Evaluation of  
477 Microglial Activation in Non-neurodegenerative Brain Diseases. *Curr. Neurol. Neurosci. Rep.*  
478 19, 38. doi:10.1007/s11910-019-0951-x.
- 479 Giorgio, A., and De Stefano, N. (2010). Cognition in multiple sclerosis: Relevance of lesions, brain  
480 atrophy and proton MR spectroscopy. *Neurol. Sci.* 31. doi:10.1007/s10072-010-0370-x.
- 481 Hamelin, L., Lagarde, J., Dorothé, G., Leroy, C., Labit, M., Comley, R. A., et al. Early and protective  
482 microglial activation in Alzheimer's disease: a prospective study using 18 F-DPA-714 PET  
483 imaging. doi:10.1093/brain/aww017.
- 484 Haris, M., Cai, K., Singh, A., Hariharan, H., and Reddy, R. (2011). In vivo mapping of brain myo-  
485 inositol. *Neuroimage* 54, 2079–2085. doi:10.1016/j.neuroimage.2010.10.017.
- 486 Kauppinen, R. A., Vidyasagar, R., Childs, C., Balanos, G. M., and Hiltunen, Y. (2008). Assessment  
487 of human brain temperature by <sup>1</sup>H MRS during visual stimulation and hypercapnia. *NMR*  
488 *Biomed.* 21, 388–395. doi:10.1002/nbm.1204.
- 489 Lucas, S.-M., Rothwell, N. J., and Gibson, R. M. (2006). The role of inflammation in CNS injury and  
490 disease. *Br. J. Pharmacol.* 147 Suppl 1, S232–40. doi:10.1038/sj.bjp.0706400.
- 491 Maroso, M., Balosso, S., Ravizza, T., Liu, J., Aronica, E., Iyer, A. M., et al. (2010). Toll-like receptor  
492 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce  
493 seizures. *Nat. Med.* 16, 413–419. doi:10.1038/nm.2127.
- 494 Maudsley, A. A., Darkazanli, A., Alger, J. R., Hall, L. O., Schuff, N., Studholme, C., et al. (2006).  
495 Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging. *NMR*  
496 *Biomed.* 19, 492–503. doi:10.1002/nbm.1025.
- 497 Maudsley, A. A., Domenig, C., and Sheriff, S. (2010). Reproducibility of serial whole-brain MR  
498 Spectroscopic Imaging. *NMR Biomed.* 23, 251–256. doi:10.1002/nbm.1445.
- 499 Maudsley, A. A., Goryawala, M. Z., and Sheriff, S. (2017). Effects of tissue susceptibility on brain  
500 temperature mapping. *Neuroimage* 146, 1093–1101. doi:10.1016/j.neuroimage.2016.09.062.
- 501 McNair, D., Lorr, M., and Droppleman, L. F. (1989). Profile of mood states (POMS). *Douglas M.*  
502 *McNair, Maurice Lorr, Leo F. Droppleman.*
- 503 Moffett, J., Ross, B., Arun, P., Madhavarao, C., and Namboodiri, A. (2007). N-Acetylaspartate in the  
504 CNS: from neurodiagnostics to neurobiology. *Prog Neurobiol* 81.
- 505 Mueller, C., Lin, J. C., Sheriff, S., Maudsley, A. A., and Younger, J. W. (2019). Evidence of  
506 widespread metabolite abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome:  
507 assessment with whole-brain magnetic resonance spectroscopy. *Brain Imaging Behav.*  
508 doi:10.1007/s11682-018-0029-4.
- 509 Mueller, C., Lin, J. C., Thannickal, H. H., Daredia, A., Denney, T. S., Beyers, R., et al. (2020). No  
510 evidence of abnormal metabolic or inflammatory activity in the brains of patients with  
511 rheumatoid arthritis: results from a preliminary study using whole-brain magnetic resonance  
512 spectroscopic imaging (MRSI). *Clin. Rheumatol.* 39, 1765–1774. doi:10.1007/s10067-019-



**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**


- 513 04923-5.
- 514 Oz, G., Alger, J. R., Barker, P. B., Bartha, R., Bizzi, A., Boesch, C., et al. (2014). Clinical proton MR  
515 spectroscopy in central nervous system disorders. *Radiology* 270, 658–79.  
516 doi:10.1148/radiol.13130531.
- 517 Rango, M., Bonifati, C., and Bresolin, N. (2015). Post-Activation Brain Warming: A 1-H MRS  
518 Thermometry Study. *PLoS One* 10, e0127314. doi:10.1371/journal.pone.0127314.
- 519 Rossi, S., Roncati Zanier, E., Mauri, I., Columbo, A., and Stocchetti, N. (2001). Brain temperature,  
520 body core temperature, and intracranial pressure in acute cerebral damage. *J. Neurol.*  
521 *Neurosurg. Psychiatry* 71, 448–454. doi:10.1136/jnnp.71.4.448.
- 522 Salmenpera, M., Symms, M. R., Rugg-Gunn, F. J., Boulby, P. A., Free, S. L., Barker, J., et al. (2007).  
523 Evaluation of Quantitative Magnetic Resonance Imaging Contrasts in MRI-Negative Refractory  
524 Focal Epilepsy \* §Tuuli. *Epilepsia* 48, 229–237. doi:10.1111/j.1528-1167.2007.00918.x.
- 525 Sharma, A. A., and Szaflarski, J. P. (2020). In Vivo Imaging of Neuroinflammatory Targets in  
526 Treatment-Resistant Epilepsy. *Curr. Neurol. Neurosci. Rep.* 20. doi:10.1007/s11910-020-1025-  
527 9.
- 528 Sharma, H. S., and Hoopes, P. J. (2003). Hyperthermia induced pathophysiology of the central  
529 nervous system. in *International Journal of Hyperthermia (Int J Hyperthermia)*, 325–354.  
530 doi:10.1080/0265673021000054621.
- 531 Shechtman, O. (2013). “The Coefficient of Variation as an Index of Measurement Reliability,” in  
532 (Springer, Berlin, Heidelberg), 39–49. doi:10.1007/978-3-642-37131-8\_4.
- 533 Thrippleton, M. J., Parikh, J., Harris, B. A., Hammer, S. J., Semple, S. I. K., Andrews, P. J. D., et al.  
534 (2014). Reliability of MRSI brain temperature mapping at 1.5 and 3 T. *NMR Biomed.* 27, 183–  
535 190. doi:10.1002/nbm.3050.
- 536 Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., et al.  
537 (2002). Automated anatomical labeling of activations in SPM using a macroscopic anatomical  
538 parcellation of the MNI MRI single-subject brain. *Neuroimage* 15, 273–289.  
539 doi:10.1006/nimg.2001.0978.
- 540 Veenith, T. V., Mada, M., Carter, E., Grossac, J., Newcombe, V., Outtrim, J., et al. (2014).  
541 Comparison of Inter Subject Variability and Reproducibility of Whole Brain Proton  
542 Spectroscopy. *PLoS One* 9, e115304. doi:10.1371/journal.pone.0115304.
- 543 Verius, M., Frank, F., Gizewski, E., and Broessner, G. (2019). Magnetic Resonance Spectroscopy  
544 Thermometry at 3 Tesla: Importance of Calibration Measurements. *Ther. Hypothermia Temp.*  
545 *Manag.* 9, 146–155. doi:10.1089/ther.2018.0027.
- 546 Vivash, L., and O'Brien, T. J. (2016). Imaging Microglial Activation with TSPO PET: Lighting Up  
547 Neurologic Diseases? *J. Nucl. Med.* 57, 165–168. doi:10.2967/jnumed.114.141713.
- 548 Wang, H., Wang, B., Normoyle, K. P., Jackson, K., Spitler, K., Sharrock, M., et al. (2014). Brain  
549 temperature and its fundamental properties: A review for clinical neuroscientists. *Front.*

**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**

- 550        *Neurosci.* 8. doi:10.3389/fnins.2014.00307.
- 551        Wang, Z., Aguirre, G. K., Rao, H., Wang, J., Fernández-Seara, M. A., Childress, A. R., et al. (2008).  
552        Empirical optimization of ASL data analysis using an ASL data processing toolbox: ASLtbx.  
553        *Magn. Reson. Imaging* 26, 261–269. doi:10.1016/j.mri.2007.07.003.
- 554        Weir, J. P. (2005). Quantifying test-retest reliability using the intraclass correlation coefficient and  
555        the SEM. *J. Strength Cond. Res.* 19, 231–240. doi:10.1519/15184.1.
- 556        Zhang, Y., Taub, E., Mueller, C., Younger, J., Uswatte, G., DeRamus, T. P., et al. (2020).  
557        Reproducibility of whole-brain temperature mapping and metabolite quantification using  
558        proton magnetic resonance spectroscopy. *NMR Biomed.* 33. doi:10.1002/nbm.4313.
- 559        Zhu, M., Ackerman, J. J. H., and Yablonskiy, D. A. (2009). Body and brain temperature coupling:  
560        The critical role of cerebral blood flow. *J. Comp. Physiol. B Biochem. Syst. Environ. Physiol.*  
561        doi:10.1007/s00360-009-0352-6.
- 562        Zigmond, A. S., and Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. *Acta*  
563        *Psychiatr. Scand.* doi:10.1111/j.1600-0447.1983.tb09716.x.
- 564
-

**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**

**1 FIGURES**




**Figure 1.** Graphical illustration of mean brain temperature for time1 (mean 37.0°C) and time2 (37.4°C) across 47 regions of interest (ROIs) delineated by the modified Automated Anatomical

---

Labeling (AAL) atlas. Brain temperature was derived using the frequency difference between water and creatine ( $T_{CRE}$ ) following processing of volumetric MRSI data. For each brain region, colored bars (Time1, teal; Time2, burgundy), reflect the mean  $T_{CRE}$ ; whiskers indicate range of  $T_{CRE}$  values beyond the mean. The mean global brain temperature over all subjects was  $37.2^{\circ}\text{C}$  with spatial variations across ROIs ( $37.57 - 41.49^{\circ}\text{C}$ ). There was a significant main effect for time ( $F(1, 1591)=37.0, p < 0.0001$ ) and for brain region ( $F(46, 1591)=2.66, p<0.0001$ ). The time\*brain region interaction was not significant ( $F(46, 1591)=0.80, p=0.83$ ). Abbreviations: MRSI, magnetic resonance spectroscopic imaging; ROI, region of interest; n, number of observations; R, right; L, left.

**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**




**Figure 2.** Mean  $T_{CRE}$  for each ROI, with Minimal Detectable Change (MDC) upper bounds indicated in dark gray bands and MDC lower bounds indicated in light gray bands.



**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**


---

## Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS



**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**

**Figure 3.** Representative axial slices showing brain temperature ( $T_{CRE}$ ) and cerebral blood flow (CBF) for 18 healthy participants at time1 and time 2.  $T_{CRE}$  and mean CBF maps were resliced and co-registered to MNI space in SPM12 running in MatLab R2017b. The open-source software MRIcroGL (McCausland Center for Brain Imaging, University of South Carolina; <https://www.mccauslandcenter.sc.edu/mricrogl/>) was used to overlay mean  $T_{CRE}$  and CBF maps on the MNI single-participant template for 3D renderings of participant data. The figure was created using BioRender. All data are visualized for axial view of the same slice ( $z = 8$ ; L, left; R; right). The  $T_{CRE}$  color scale ranges from 36.0 – 39°C, with dark to light blue coloring indicating  $T_{CRE}$  values within the typical range. The majority of voxels demonstrate  $T_{CRE} < 37.5^\circ\text{C}$ , with a mean of 37.0°C for time1 and 37.4°C for time2 (global mean of 37.2°C). As demonstrated by the time1 and time2 maps and the global COVrep of 1.92%, there was a minimal variation in participants’ data from time1 to time2. For some participants’ data, brain regions were excluded from analysis due to technical reasons; these areas are represented by regions where the template brain is exposed. Each participant’s mean CBF maps for time1 and time 2 are visualized alongside  $T_{CRE}$  maps; as with  $T_{CRE}$  mean CBF varies little from time1 to time2. Spatial  $T_{CRE}$  variations did not vary as a function of cerebral perfusion as indicated by mean CBF.



**Figure 4.** Regional distribution of reference metabolites N-Acetylaspartate (NAA), creatine (total creatine, tCre), and choline (total choline, tCho) at time 1.

## 2 TABLES

**Table 1.** Descriptive statistics for clinical and imaging-derived measures of temperature, blood flow, or inflammatory processes.

	<b>Time 1 (N=18)</b>	<b>Time 2 (N=18)</b>	<b>Time 1 vs Time 2</b>
Heart Rate (bpm)	73.50 ±11.40	74.17 ±17.12	$t(17)=-0.20, p=0.84$
HADS, Depression	1.72 ±1.96	2.72 ±2.27	$t(17)=-4.12, p=0.001$
HADS, Anxiety	5.33 ±2.63	4.83 ±2.36	$t(17)=0.89, p=0.39$
POMS, TMD	-0.39 ±20.75	0.06 ±18.89	$t(17)=-0.18, p=0.85$
Tympanic Temperature (°C)	36.73 ±0.30	36.65 ±0.19	$t(17)=0.98, p=0.34$
Global T <sub>CRE</sub> (°C)	37.00 ±0.62	37.40 ±0.94	$t(17)=-1.28, p=0.22$
Global CBF (ml/100g/min)	70.77 ±6.15	71.03 ±4.24	$t(17)=0.21, p=0.84$
tCre	26270.0 ±1807	26844.98 ±1345.20	$t(17)=-1.91, p=0.07$
tCho	5279.00 ±664.10	5288.66 ±723.35	$t(17)=-0.10, p=0.93$
NAA/tCre	1.35 ±0.24	1.26 ±0.09	$t(17)=2.19, p=0.04$
Glx/tCre	0.66 ±0.06	0.64 ±0.05	$t(17)=1.76, p=0.10$
MI/tCre	0.55 ±0.08	0.59 ±0.22	$t(17)=-0.63, p=0.53$

\*All measures are in I.U., institutional units unless otherwise specified.

Abbreviations: HADS – Hospital Anxiety and Depression Scale; POMS – Profile of Mood States; TMD – total mood disturbance; CBF, cerebral blood flow; tCHO, total choline; tCre, creatine + phosphocreatine (total creatine); NAA/tCre, N-acetylaspartate + N-acetylaspartyl glutamate ratio to tCre; Glx/tCr, ratio of combined signal from glutamine and glutamate to tCre; MI/tCre, myo-inositol ratio to tCre.

**Table 2.** Mean MRSI-based brain temperature (T<sub>CRE</sub>) in 47 ROIs for both time points time1 (T<sub>1</sub>) and time2 (T<sub>2</sub>), their standard deviations (SD), and corresponding reproducibility and reliability statistics. For each ROI, reproducibility was measured with the coefficient of variation for repeated measures (COV<sub>rep</sub>). The standard error of measurement (SEM) provided a measure of reliability. Minimal Detectable Change (MDC) was calculated from SEM to provide a clinically meaningful basis for evaluating T<sub>CRE</sub> changes over repeated measures.

<b>ROI</b>	<b>Scan</b>	<b>n</b>	<b>Mean</b>	<b>SD</b>	<b>COV<sub>rep</sub></b>	<b>SEM</b>	<b>MDC</b>
					<b>(%)</b>		
<b>L Calcarine</b>	T <sub>1</sub>	18	37.320	1.019	1.85	1.131	1.600
	T <sub>2</sub>	18	37.289	1.244			
<b>R Calcarine</b>	T <sub>1</sub>	18	37.306	1.052	2.24	1.288	1.822
	T <sub>2</sub>	18	37.247	1.421			
<b>L Caudate</b>	T <sub>1</sub>	18	36.788	0.963	1.66	0.733	1.036
	T <sub>2</sub>	18	37.106	0.807			
<b>R Caudate</b>	T <sub>1</sub>	18	36.921	0.800	1.73	0.827	1.170
	T <sub>2</sub>	18	36.922	0.721			
<b>Cerebellum</b>	T <sub>1</sub>	18	36.822	0.848	2.10	1.141	1.614



**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**

	T <sub>2</sub>	18	37.497	1.436			
<b>L Anterior Cingulum</b>	T <sub>1</sub>	17	36.853	0.807	1.29	0.581	0.822
	T <sub>2</sub>	17	36.641	0.606			
<b>R Anterior Cingulum</b>	T <sub>1</sub>	17	36.965	0.799	1.11	0.511	0.722
	T <sub>2</sub>	17	36.806	0.610			
<b>L Mid Cingulum</b>	T <sub>1</sub>	18	37.345	0.597	0.81	0.365	0.516
	T <sub>2</sub>	18	37.512	0.383			
<b>R Mid Cingulum</b>	T <sub>1</sub>	18	37.387	0.661	0.88	0.421	0.595
	T <sub>2</sub>	18	37.600	0.391			
<b>L Posterior Cingulum</b>	T <sub>1</sub>	18	37.363	0.735	1.41	0.824	1.165
	T <sub>2</sub>	18	37.262	0.875			
<b>R Posterior Cingulum</b>	T <sub>1</sub>	18	37.364	0.605	1.36	0.696	0.985
	T <sub>2</sub>	18	37.366	0.698			
<b>L Cuneus</b>	T <sub>1</sub>	18	37.062	1.257	2.50	1.522	2.153
	T <sub>2</sub>	18	38.140	1.835			
<b>R Cuneus</b>	T <sub>1</sub>	18	37.161	1.316	2.65	1.586	2.243
	T <sub>2</sub>	18	38.138	1.620			
<b>L Frontal Lobe</b>	T <sub>1</sub>	18	37.431	1.787	2.88	2.713	3.837
	T <sub>2</sub>	18	37.884	2.582			
<b>R Frontal Lobe</b>	T <sub>1</sub>	17	37.445	1.759	2.56	2.395	3.387
	T <sub>2</sub>	17	37.771	2.285			
<b>L Fusiform Gyrus</b>	T <sub>1</sub>	18	36.909	1.065	1.60	0.831	1.176
	T <sub>2</sub>	18	37.221	0.959			
<b>R Fusiform Gyrus</b>	T <sub>1</sub>	18	36.601	1.108	3.08	2.179	3.082
	T <sub>2</sub>	18	38.067	2.735			
<b>L Hippocampus</b>	T <sub>1</sub>	18	36.758	0.616	1.55	0.879	1.243
	T <sub>2</sub>	18	36.674	0.902			
<b>R Hippocampus</b>	T <sub>1</sub>	18	36.278	0.956	2.13	1.016	1.437
	T <sub>2</sub>	18	36.824	0.980			
<b>L Insula</b>	T <sub>1</sub>	18	36.854	0.996	1.92	1.022	1.446
	T <sub>2</sub>	18	37.126	0.978			
<b>R Insula</b>	T <sub>1</sub>	18	36.572	0.991	1.93	0.934	1.321
	T <sub>2</sub>	18	36.979	0.897			
<b>L Lingual Gyrus</b>	T <sub>1</sub>	18	37.213	1.134	1.89	1.111	1.572
	T <sub>2</sub>	18	37.120	1.161			
<b>R Lingual Gyrus</b>	T <sub>1</sub>	18	37.096	1.021	1.61	0.853	1.206
	T <sub>2</sub>	18	37.355	0.594			
<b>L Occipital Lobe</b>	T <sub>1</sub>	18	37.326	1.761	1.33	0.731	1.033
	T <sub>2</sub>	18	37.696	2.106			
<b>R Occipital Lobe</b>	T <sub>1</sub>	18	37.179	0.879	2.98	2.507	3.546
	T <sub>2</sub>	18	38.484	3.504			
<b>L Pallidum</b>	T <sub>1</sub>	18	36.749	1.776	2.58	1.195	1.691
	T <sub>2</sub>	18	36.693	1.005			
<b>R Pallidum</b>	T <sub>1</sub>	17	36.406	1.381	2.70	1.292	1.828
	T <sub>2</sub>	17	36.483	0.939			
<b>L Paracentral Lobule</b>	T <sub>1</sub>	18	37.124	1.151	1.49	0.663	0.937



**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**

	T <sub>2</sub>	18	37.603	0.692			
<b>R Paracentral Lobule</b>	T <sub>1</sub>	18	37.409	1.073	1.66	1.430	2.023
	T <sub>2</sub>	18	37.761	1.190			
<b>L Parietal Lobe</b>	T <sub>1</sub>	18	36.921	1.349	2.57	2.564	3.627
	T <sub>2</sub>	18	37.877	2.485			
<b>R Parietal Lobe</b>	T <sub>1</sub>	18	36.998	1.424	2.47	2.414	3.414
	T <sub>2</sub>	18	38.016	2.307			
<b>L Postcentral Gyrus</b>	T <sub>1</sub>	18	36.994	1.232	2.35	2.420	3.422
	T <sub>2</sub>	18	37.851	2.350			
<b>R Postcentral Gyrus</b>	T <sub>1</sub>	18	37.084	1.157	1.88	2.003	2.833
	T <sub>2</sub>	18	37.850	1.944			
<b>L Precentral Gyrus</b>	T <sub>1</sub>	18	36.984	1.315	2.57	2.609	3.690
	T <sub>2</sub>	18	37.891	2.625			
<b>R Precentral Gyrus</b>	T <sub>1</sub>	18	37.028	1.459	2.40	2.216	3.133
	T <sub>2</sub>	18	37.793	2.211			
<b>L Precuneus</b>	T <sub>1</sub>	18	37.399	0.867	1.69	1.222	1.728
	T <sub>2</sub>	18	37.920	1.134			
<b>R Precuneus</b>	T <sub>1</sub>	18	37.382	1.002	1.73	1.341	1.897
	T <sub>2</sub>	18	37.944	1.201			
<b>L Putamen</b>	T <sub>1</sub>	18	36.392	1.105	2.18	1.029	1.455
	T <sub>2</sub>	18	36.808	0.911			
<b>R Putamen</b>	T <sub>1</sub>	18	36.248	0.975	1.89	0.872	1.233
	T <sub>2</sub>	18	36.511	0.849			
<b>L Rolandic Operculum</b>	T <sub>1</sub>	18	37.013	0.821	1.76	1.289	1.823
	T <sub>2</sub>	18	37.419	1.328			
<b>R Rolandic Operculum</b>	T <sub>1</sub>	18	36.983	0.830	1.51	0.757	1.071
	T <sub>2</sub>	18	37.360	0.582			
<b>L Supplemental Motor Area</b>	T <sub>1</sub>	18	37.187	0.872	1.66	1.301	1.840
	T <sub>2</sub>	18	37.547	1.190			
<b>R Supplemental Motor Area</b>	T <sub>1</sub>	17	37.251	0.837	1.67	1.295	1.831
	T <sub>2</sub>	17	37.496	1.142			
<b>L Temporal Lobe</b>	T <sub>1</sub>	18	36.971	0.569	1.24	1.111	1.571
	T <sub>2</sub>	18	37.308	1.981			
<b>R Temporal Lobe</b>	T <sub>1</sub>	18	36.634	0.822	1.72	1.197	1.694
	T <sub>2</sub>	18	37.182	1.529			
<b>L Thalamus</b>	T <sub>1</sub>	18	36.823	0.696	1.57	0.853	1.207
	T <sub>2</sub>	18	36.748	1.059			
<b>R Thalamus</b>	T <sub>1</sub>	18	36.715	0.886	1.94	1.004	1.420
	T <sub>2</sub>	18	36.824	1.104			

Abbreviations: MRSI, magnetic resonance spectroscopic imaging; ROI, region of interest; n, number of observations; R, right; L, left.

**Table 4.** Coefficient of variation (COV<sub>rep</sub>, %) for major metabolites.

**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**

<b>Brain Region</b>	<b>COVrep (%)</b>			
	<b>tCho</b>	<b>tCre</b>	<b>MI</b>	<b>NAA</b>
<b>L Calcarine</b>	7.27	8.94	5.47	13.43
<b>R Calcarine</b>	11.63	14.42	10.59	13.00
<b>L Caudate</b>	12.03	7.93	8.53	22.89
<b>R Caudate</b>	19.00	10.67	6.62	24.31
<b>Cerebellum</b>	10.61	17.31	28.44	20.28
<b>L Anterior Cingulum</b>	6.20	8.78	4.71	14.59
<b>R Anterior Cingulum</b>	6.85	6.41	3.43	12.83
<b>L Mid Cingulum</b>	9.62	9.44	3.18	13.89
<b>R Mid Cingulum</b>	5.26	11.24	2.68	17.67
<b>L Posterior Cingulum</b>	4.73	6.45	5.01	7.19
<b>R Posterior Cingulum</b>	10.62	6.10	4.58	6.41
<b>L Cuneus</b>	7.29	10.71	7.58	9.37
<b>R Cuneus</b>	8.04	12.06	11.11	11.07
<b>L Frontal Lobe</b>	4.33	7.18	4.76	8.68
<b>R Frontal Lobe</b>	12.79	4.39	3.28	9.58
<b>L Fusiform Gyrus</b>	15.91	10.46	10.02	18.75
<b>R Fusiform Gyrus</b>	10.84	13.19	19.78	20.94
<b>L Hippocampus</b>	12.45	11.14	7.72	11.01
<b>R Hippocampus</b>	15.24	10.46	10.74	12.08
<b>L Insula</b>	3.13	6.79	3.48	19.45
<b>R Insula</b>	34.44	6.60	4.63	17.07
<b>L Lingual Gyrus</b>	10.53	12.34	10.68	17.38
<b>R Lingual Gyrus</b>	16.60	13.27	13.28	16.60
<b>L Occipital Lobe</b>	5.76	9.93	6.63	11.15
<b>R Occipital Lobe</b>	9.08	12.74	8.48	9.53
<b>L Pallidum</b>	12.41	10.15	8.04	41.97
<b>R Pallidum</b>	12.70	17.14	8.88	37.91
<b>L Paracentral Lobule</b>	17.79	17.57	6.26	22.12
<b>R Paracentral Lobule</b>	16.46	20.08	5.93	29.10
<b>L Parietal Lobe</b>	4.47	6.30	3.49	6.54
<b>R Parietal Lobe</b>	10.22	5.44	4.29	6.77
<b>L Postcentral Gyrus</b>	10.16	10.10	4.18	9.89
<b>R Postcentral Gyrus</b>	10.58	11.64	4.13	12.59
<b>L Precentral Gyrus</b>	11.91	12.20	4.56	16.17
<b>R Precentral Gyrus</b>	84.52	11.54	4.72	14.53
<b>L Precuneus</b>	6.94	5.99	4.21	7.87
<b>R Precuneus</b>	7.82	6.65	3.09	10.72
<b>L Putamen</b>	6.23	6.94	4.91	30.85
<b>R Putamen</b>	13.48	9.99	7.32	22.54
<b>L Rolandic Operculum</b>	4.07	6.96	4.25	7.96
<b>R Rolandic Operculum</b>	4.72	8.29	4.30	9.05
<b>L Supplemental Motor Area</b>	14.95	19.46	7.08	32.60
<b>R Supplemental Motor Area</b>	22.56	22.08	4.86	25.93
<b>L Temporal Lobe</b>	3.70	4.35	3.78	8.12
<b>R Temporal Lobe</b>	8.23	5.15	6.17	6.48

**Running title: REPEATABILITY OF BRAIN TEMPERATURE MEASUREMENTS**

<b>L Thalamus</b>	11.69	8.28	7.63	14.71
<b>R Thalamus</b>	21.24	12.43	8.35	20.60

Abbreviations: L, left; R, right; tCHO, total choline; tCre, creatine + phosphocreatine (total creatine); MI, myo-inositol; NAA, N-acetylaspartate + N- acetylaspartyl glutamate ratio.

**Table 6.** Pearson correlations between measures of reproducibility and repeatability (SEM and COVrep), mean T<sub>CRE</sub>, and ROI size. All correlations significant at the 0.01 level (2-tailed).

	<b>SEM, z-score</b>	<b>COVrep, z-score</b>	<b>Mean T<sub>CRE</sub>, z-score</b>	<b>ROI Size, z-score</b>
<b>SEM, z-score</b>	-	0.805	0.487	0.524
<b>COVrep, z-score</b>	0.805	-		
<b>Mean T<sub>CRE</sub>, z-score</b>	0.487		-	0.626
<b>ROI size, z-score</b>	0.524		0.626	-